Immutep (ASX:IMM) has announced that the first participant has been successfully dosed in the first-in human Phase 1 trial of IMP761.
The company is developing novel LAG-3 immunotherapies for cancer and autoimmune disease.
IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the 'brake' function of LAG-3 to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases.
The Centre for Human Drug Research in the Netherlands is conducting a single and multiple ascending dose, placebo-controlled, double-blind Phase 1 study. The study aims to enrol 49 healthy volunteers and assess safety, pharmacokinetics, and pharmacodynamics.
The company said it anticipates the first safety data from the study to be available before the end of the year, with an assessment of the pharmacokinetic and pharmacodynamic relationships to follow in the first half of the calendar year 2025.
